MMP13 and cancer: In regard to rs2252070 polymorphism, the overall P values and odds ratios demonstrate no significant rising or declining link between MMP13 rs2252070 polymorphism and cancer risk, whatever the genotype (B vs. A [OR = 1.009, 95%Cl = 0.882–1.154, P = .894]; BB vs. AA [OR = 1.021, 95% Cl = 0.777–1.343, P = .88]; BA vs. AA [OR = 0.986, 95%Cl = 0.785–1.238, P = .902]; BB + BA vs. AA [OR = 0.996, 95% Cl = 0.803–1.236, P = .974]; BB vs. BA + AA [OR = 1.031, 95%Cl = 0.821–1.295, P = .793]).